Eckel Florian, Lersch Christian, Assmann Gerald, Schulte-Frohlinde Ewert
Department of Internal Medicine II, Technical University of Munich, Klinikum rechts der Isar, Ismaningerstr. 22, 81675 Munich, Germany.
Cancer Invest. 2002;20(2):180-5. doi: 10.1081/cnv-120001144.
The antitumor activity of gemcitabine is not dose-response related but schedule-dependent. Based on the results of a published phase I study in patients with nonsmall-cell lung cancer we started a pilot study of a 24-hr infusion of gemcitabine in patients with adenocarcinoma of the pancreas and biliary tract cancer. Twenty-five patients were enrolled and received a 24-hr infusion of gemcitabine once weekly on three consecutive out of 4 weeks. Dose levels of gemcitabine ranged from 100 to 150 mg/m2. One of 13 chemotherapy-naive patients had a partial response. Dose-limiting toxicity (DLT) was thrombocytopenia in pretreated patients and neutropenia in chemotherapy-naive patients. Other toxicities were oral mucositis, fever, flu-like symptoms, and asthenia. Maximum tolerated dose (MTD), especially in pretreated patients, was 100 mg/m2.
吉西他滨的抗肿瘤活性与剂量反应无关，而是与给药方案有关。基于一项已发表的非小细胞肺癌患者I期研究结果，我们开展了一项针对胰腺癌和胆管癌患者的吉西他滨24小时持续静脉输注的初步研究。25例患者入组，在4周中的连续3周内每周接受一次吉西他滨24小时持续静脉输注。吉西他滨的剂量水平为100至150mg/m²。13例初治患者中有1例出现部分缓解。剂量限制性毒性（DLT）在经治患者中为血小板减少，在初治患者中为中性粒细胞减少。其他毒性反应包括口腔黏膜炎、发热、流感样症状和乏力。最大耐受剂量（MTD），尤其是在经治患者中，为100mg/m²。
